Cue Biopharma, Inc.

Cue Biopharma Inc. is a biotechnology company focused on developing innovative biologic drugs that can precisely modulate the human immune system. The company's primary purpose is to create therapies that can selectively enhance or inhibit immune responses, potentially leading to treatments for a wide array of diseases, including cancer and autoimmune disorders. A notable feature of Cue Biopharma is its proprietary drug development platform, Immuno-STAT, designed to target specific T cells in the immune system, thereby refining the activation or suppression of immune processes. This targeted approach could impact several sectors, particularly oncology and immunotherapy, by offering more targeted and potentially effective treatment options. Founded in 2014 and based in Massachusetts, Cue Biopharma is a key player in the biotechnology industry, contributing to the growing body of research and development in precision medicine. Its work has significant market implications, as the demand for personalized medicine and immunotherapies continues to rise, reflecting broader trends in healthcare innovation and therapeutic development.